Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Carcinoma, Neuroendocrine 2Carcinoma 1Carcinoid Tumor 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × azaspirane × Clear all
NCT00663429 2011-08-31

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

Callisto Pharmaceuticals

Phase 2 Completed
10 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT00388063 2007-12-21

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Callisto Pharmaceuticals

Phase 2 Completed
55 enrolled
Endocrine

Carcinoid Tumor, Carcinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡